^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BHG712

    i
    Other names: BHG712, NVP-BHG712
    Company:
    Novartis
    Drug class:
    EphB4 inhibitor
    Related drugs:
    20d
    A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer. (PubMed, Discov Oncol)
    In conclusion, we constructed five cuprotosis-related lncRNA prognostic models, which may be new tumor therapeutic targets for the prevention and treatment of cervical cancer.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    |
    BHG712 • OSI-930 • Kinaction (masitinib)
    11ms
    Comprehensive bioinformatics and experimental analysis of SH3PXD2B reveals its carcinogenic effect in gastric carcinoma. (PubMed, Life Sci)
    Our study strongly suggests that SH3PXD2B is a carcinogenic molecule that can be used as a biomarker for GC detection, prognosis, treatment design, and follow-up.
    Journal
    |
    ADAM15 (ADAM Metallopeptidase Domain 15) • SH3PXD2B (SH3 And PX Domains 2B)
    |
    sirolimus • sotrastaurin (AEB071) • BHG712
    1year
    Optimization of the Lead Compound NVP-BHG712 as Colorectal Cancer Inhibitor. (PubMed, Chemistry)
    Testing in up to seven colon cancer cell lines that express EPHA2 reveals that several derivatives feature promising effects for control of human colon carcinoma. Thus, we have developed a set of powerful tool compounds for fundamental new research on the interplay of EPH receptors in a cellular context.
    Journal
    |
    EPHA2 (EPH receptor A2)
    |
    BHG712
    over1year
    Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic cancer. (PubMed, Comput Biol Med)
    Finally, we suggested KGs-guided five repurposable drug molecules (Linsitinib, CX5461, Irinotecan, Timosaponin AIII, and Olaparib) and a new molecule (NVP-BHG712) against PC by molecular docking. The cross-validation and some literature reviews also supported our findings. Therefore, the finding of this study might be useful resources to the researchers and medical doctors for diagnosis, prognosis and therapies of PC by the wet-lab validation.
    Journal • Gene Expression Profile • PARP Biomarker
    |
    ADAM10 (ADAM Metallopeptidase Domain 10) • ITGB1 (Integrin Subunit Beta 1) • ITGB5 (Integrin Subunit Beta 5)
    |
    Lynparza (olaparib) • irinotecan • pidnarulex (CX-5461) • linsitinib (ASP7487) • BHG712